Inhibition of β-AR signaling by receptor antagonists (beta blockers) has become the gold standard treatment for the benign vascular tumor infantile hemangioma [27, 29], in part through disrupting tumor cell proliferation [30]. The gene discussed is ADRB2; the disease is neoplasm.